ArticleCell2023
Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway.
Open access · greenAbstract read
In one paragraph
Article in Cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
20.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 135 citations in OpenAlex.
- SUMOylated Reptin maintains low intracellular ROS levels by activating mitophagy to drive gemcitabine resistance in gallbladder cancer.Cell death & disease · 2026Article
- Article
- Systematic Targeting of Protein Complexes with Molecular COUPLrs.Cancer discovery · 2026Article
- Spermine oxidase-DOX conjugates reshape tumor microenvironment via carbonyl stress to potentiate bladder cancer chemotherapy.Materials today. Bio · 2026Article
- Multifunctional nanotherapeutics for targeted modulation of endoplasmic reticulum stress to potentiate cancer therapy.Asian journal of pharmaceutical sciences · 2026Review
- Mitochondria-transliterated ALDH1L1 functions as a feedback regulator of redox homeostasis in cancer cells to enhance the resistance to pro-oxidative therapy.Cell death and differentiation · 2026Article
- Defining and refining the cysteine redoxome through sulfur chemical biology.Nature chemical biology · 2026Review
- Cysteine addiction in drug resistant glioblastoma and therapeutic targeting with designer selenium compounds.Neuro-oncology · 2026Article
- Atlas-Guided Nanocarrier Strategies Targeting Spatial NTRK2/MAPK Signaling in EGFR-TKI-Resistant Niches of Esophageal Squamous Cell Carcinoma.Pharmaceutics · 2026Review
- Effects of Mechanical Stress on Bone and Cartilage Metabolism: How Mechanical Stress Affects Energy Metabolism in Bone and Cartilage Tissues (Our Research Overview): Mini Review.International journal of molecular sciences · 2026Review
- SRSF2 mutations drive daunorubicin resistance in acute myeloid leukemia via THBS1 stabilization.Journal of experimental & clinical cancer research : CR · 2026Article
- Targeting mitochondrial homeostasis as a cancer treatment strategy: current status and future prospects.Molecular cancer · 2026Review
- Mitochondrial retrograde signal through GCN5L1 transition-mediated PPARγ stabilization promotes MASLD development.JCI insight · 2026Article
- CHK1 as a Metabolic and Immunological Regulator: Implications for Cancer Therapy.Oncology research · 2026Review
- CUL2 confers ferroptosis resistance in pancreatic cancer by disrupting KEAP1-mediated NRF2 degradation.Cancer cell international · 2025Article
- HMGB3 promotes brain metastasis of lung adenocarcinoma by recruiting SSBP1 for nuclear translocation to remodel mitochondrial metabolism.Cancer communications (London, England) · 2025Article
- Ferroptosis-associated transcriptional factors in neurological diseases: molecular mechanisms and therapeutic prospects.Experimental & molecular medicine · 2025Review
- Mitochondria-targeted MXene@MnOBioactive materials · 2025Article
- Mitochondrial complex III-derived ROS amplify immunometabolic changes in astrocytes and promote dementia pathology.Nature metabolism · 2025Article
- Enhancing biological imaging with high-performance probes based on thermally activated delayed fluorescence.iScience · 2025Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Update of
Authors and funding
38 authors at 4 institutions in 1 country.
Junbing ZhangCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA. Electronic address: jzhang75@mgh.harvard.edu.
Claire M SimpsonCell Signaling Technology, Inc., Danvers, MA, USA.
Jacqueline BernerCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Harrison B ChongCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Jiafeng FangCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Zehra OrduluDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, USA.
Tommy Weiss-SadanCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Anthony P PossematoCell Signaling Technology, Inc., Danvers, MA, USA.
Stefan HarryCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Mariko TakahashiCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Tzu-Yi YangCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Marianne RichterCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Himani PatelCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Abby E SmithCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Alexander D CarlinCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Adriaan F Hubertus de GrootCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Konstantin WolfCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Lei ShiCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Ting-Yu WeiCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Benedikt R DürrCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Nicholas J ChenCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Tristan VornbäumenCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Nina O WichmannCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Mohammed S MahamdehDivision of Cardiology, Harvard Medical School, Boston, MA, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Venkatesh PooladandaDepartment of Obstetrics and Gynecology, Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA; Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA, USA.
Yusuke MatobaDepartment of Obstetrics and Gynecology, Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA; Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA, USA.
Shaan KumarObstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA, USA.
Eugene KimObstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA, USA.
Sara BouberhanDivision of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Esther OlivaDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Bo R RuedaDepartment of Obstetrics and Gynecology, Vincent Center for Reproductive Biology, Massachusetts General Hospital, Boston, MA, USA; Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA, USA.
Roy J SobermanDivision of Nephrology, Harvard Medical School, Boston, MA, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Nabeel BardeesyCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Brian B LiauDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.
Michael LawrenceCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Matt P StokesCell Signaling Technology, Inc., Danvers, MA, USA.
Sean A BeausoleilCell Signaling Technology, Inc., Danvers, MA, USA.
Liron Bar-PeledCenter for Cancer Research, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: lbar-peled@mgh.harvard.edu.
Massachusetts General Hospital · USHarvard University · USCell Signaling Technology (United States) · USUniversity of Florida · US
Funding
Genetic Variants in Craniofacial DystoniasR01DE030464 · NIDCR · MASSACHUSETTS GENERAL HOSPITAL · PI NUTAN SHARMA · 2022 to 2026
$3.0MMapping Structure-Activity Relationships of Chemical Inhibitors via Genome-EditingDP2GM137494 · NIGMS · HARVARD UNIVERSITY · PI LIAU, BRIAN · 2019 to 2019
$2.5MDeciphering the Role of Reductive Stress in Non Small Cell Lung CancerR37CA260062 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Liron Bar-Peled · 2022 to 2026
$1.9MMapping druggable co-dependency pathways in NRF2-driven lung cancersR00CA215249 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BAR-PELED, LIRON · 2019 to 2021
$727kChemical Proteomic Identification of Druggable Oncogenic Transcription FactorsR21CA256082 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BAR-PELED, LIRON · 2021 to 2023
$620kNCI NIH HHS R00 CA215249NCI NIH HHS R21 CA256082NCI NIH HHS R37 CA260062NIDCR NIH HHS R01 DE030464NIGMS NIH HHS DP2 GM137494
Abstract
Multiple anticancer drugs have been proposed to cause cell death, in part, by increasing the steady-state levels of cellular reactive oxygen species (ROS). However, for most of these drugs, exactly how the resultant ROS function and are sensed is poorly understood. It remains unclear which proteins the ROS modify and their roles in drug sensitivity/resistance. To answer these questions, we examined 11 anticancer drugs with an integrated proteogenomic approach identifying not only many unique targets but also shared ones-including ribosomal components, suggesting common mechanisms by which drugs regulate translation. We focus on CHK1 that we find is a nuclear H
Indexed as
Antineoplastic AgentsReactive Oxygen SpeciesCell NucleusHumansHydrogen PeroxideMitochondriaAntineoplastic AgentsHydrogen PeroxideReactive Oxygen Specieschemical proteomicschemoresistanceCHK1mitochondrial translationnuclear ROSnucleus-to-mitochondria signaling
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.